Intravenous Immunoglobulin (IVIG) Market Value to Reach US$14,923.2 Million 2024
Since the first formulation of intravenous immunoglobulin (IVIG) that gained FDA approval back in 1980s, the concept has been harnessed relentlessly in the last three decades and adverse effects have been neutralized to a large extent.
View full press release